SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
29 April 2022Let’s meet at Vitafoods 2022
The countdown to the biggest event in the dietary supplement and functional food industry, Vitafoods Europe 2022, has begun. We have...